SC-Ad6-1 / Tetherex Pharma - LARVOL DELTA

A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=196 | Completed | Sponsor: Moat Biotechnology Corporation | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=230 | Recruiting | Sponsor: Moat Biotechnology Corporation | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=190 | Recruiting | Sponsor: Tetherex Pharmaceuticals Corporation | N=130 ➔ 190 | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases